Basic Information
| Clone | Obinutuzumab Biosimilar |
|---|
| Molecular Weight | 150 kDa |
|---|
| Endotoxin | <0.05EU/mg (<0.00005EU/μg)
Determined by LAL gel clotting assay |
|---|
| Sterility | 0.2 μm filtration |
|---|
| Aggregation | <5% Determined by SECP |
|---|
| Purity | >95% Determined by SDS-PAGE |
|---|
Product Information
| Production | Purified from cell culture supernatant in an animal-free facility |
|---|
| Purification | Protein A or G purification |
|---|
| Storage | 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing) |
|---|
Target Background
Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
Immunogen Information
| Isotype | Human IgG1 kappa |
|---|
| Immunogen | Human CD20 |
|---|
| RecommendedIsotype Control(s) | In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody |
|---|
| Recommended Dilution Buffer | 1×PBS pH 7.0 |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
A1_FC_01.jpg?t=1717744805)
i_FC_01.jpg?t=1718275694)
